Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

1.

Patient-derived xenograft (PDX) models in basic and translational breast cancer research.

Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT.

Cancer Metastasis Rev. 2016 Dec;35(4):547-573. doi: 10.1007/s10555-016-9653-x.

PMID:
28025748
2.

The glucose transporter GLUT1 is required for ErbB2-induced mammary tumorigenesis.

Wellberg EA, Johnson S, Finlay-Schultz J, Lewis AS, Terrell KL, Sartorius CA, Abel ED, Muller WJ, Anderson SM.

Breast Cancer Res. 2016 Dec 20;18(1):131. doi: 10.1186/s13058-016-0795-0.

3.

Labeling of Breast Cancer Patient-derived Xenografts with Traceable Reporters for Tumor Growth and Metastasis Studies.

Hanna C, Kwok L, Finlay-Schultz J, Sartorius CA, Cittelly DM.

J Vis Exp. 2016 Nov 30;(117). doi: 10.3791/54944.

PMID:
27929464
4.

Steroid Hormone Receptor Positive Breast Cancer Patient-Derived Xenografts.

Matthews SB, Sartorius CA.

Horm Cancer. 2016 Oct 28. [Epub ahead of print]

PMID:
27796944
5.

Fibroblast subtypes regulate responsiveness of luminal breast cancer to estrogen.

Brechbuhl HM, Finlay-Schultz J, Yamamoto T, Gillen A, Cittelly DM, Tan AC, Sams SB, Pillai M, Elias A, Robinson WA, Sartorius CA, Kabos P.

Clin Cancer Res. 2016 Oct 4. pii: clincanres.2851.2015. [Epub ahead of print]

PMID:
27702820
6.

Cooperative Dynamics of AR and ER Activity in Breast Cancer.

D'Amato NC, Gordon MA, Babbs B, Spoelstra NS, Carson Butterfield KT, Torkko KC, Phan VT, Barton VN, Rogers TJ, Sartorius CA, Elias A, Gertz J, Jacobsen BM, Richer JK.

Mol Cancer Res. 2016 Nov;14(11):1054-1067.

PMID:
27565181
7.

Progestin treatment decreases CD133+ cancer stem cell populations in endometrial cancer.

Guy MS, Qamar L, Behbakht K, Post MD, Sheeder J, Sartorius CA, Spillman MA.

Gynecol Oncol. 2016 Mar;140(3):518-26. doi: 10.1016/j.ygyno.2015.12.022.

PMID:
26731726
8.

The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p.

Towers CG, Guarnieri AL, Micalizzi DS, Harrell JC, Gillen AE, Kim J, Wang CA, Oliphant MU, Drasin DJ, Guney MA, Kabos P, Sartorius CA, Tan AC, Perou CM, Espinosa JM, Ford HL.

Nat Commun. 2015 Dec 21;6:10077. doi: 10.1038/ncomms10077.

9.

Cytokeratin 5-Positive Cells Represent a Therapy Resistant subpopulation in Epithelial Ovarian Cancer.

Corr BR, Finlay-Schultz J, Rosen RB, Qamar L, Post MD, Behbakht K, Spillman MA, Sartorius CA.

Int J Gynecol Cancer. 2015 Nov;25(9):1565-73. doi: 10.1097/IGC.0000000000000553.

10.

Preface.

Clarke C, Dontu G, Hilton H, Meier-Abt F, Sartorius C.

J Mammary Gland Biol Neoplasia. 2015 Jun;20(1-2):5-7. doi: 10.1007/s10911-015-9345-0. No abstract available.

PMID:
26385464
11.

Steroid hormones, steroid receptors, and breast cancer stem cells.

Finlay-Schultz J, Sartorius CA.

J Mammary Gland Biol Neoplasia. 2015 Jun;20(1-2):39-50. doi: 10.1007/s10911-015-9340-5. Review.

12.

p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer.

Tentler JJ, Ionkina AA, Tan AC, Newton TP, Pitts TM, Glogowska MJ, Kabos P, Sartorius CA, Sullivan KD, Espinosa JM, Eckhardt SG, Diamond JR.

Mol Cancer Ther. 2015 May;14(5):1117-29. doi: 10.1158/1535-7163.MCT-14-0538-T.

13.

Live multicellular tumor spheroid models for high-content imaging and screening in cancer drug discovery.

Reid BG, Jerjian T, Patel P, Zhou Q, Yoo BH, Kabos P, Sartorius CA, Labarbera DV.

Curr Chem Genom Transl Med. 2014 Feb 7;8(Suppl 1):27-35. doi: 10.2174/2213988501408010027.

14.

Progesterone-inducible cytokeratin 5-positive cells in luminal breast cancer exhibit progenitor properties.

Axlund SD, Yoo BH, Rosen RB, Schaack J, Kabos P, Labarbera DV, Sartorius CA.

Horm Cancer. 2013 Feb;4(1):36-49. doi: 10.1007/s12672-012-0127-5.

15.

Canid progesterone receptors lack activation function 3 domain-dependent activity.

Gracanin A, van Wolferen ME, Sartorius CA, Brenkman AB, Schoonen WG, Mol JA.

Endocrinology. 2012 Dec;153(12):6104-13. doi: 10.1210/en.2012-1793.

PMID:
23041671
16.

Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.

Kabos P, Finlay-Schultz J, Li C, Kline E, Finlayson C, Wisell J, Manuel CA, Edgerton SM, Harrell JC, Elias A, Sartorius CA.

Breast Cancer Res Treat. 2012 Sep;135(2):415-32. doi: 10.1007/s10549-012-2164-8.

17.

Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways.

Iwanaga R, Wang CA, Micalizzi DS, Harrell JC, Jedlicka P, Sartorius CA, Kabos P, Farabaugh SM, Bradford AP, Ford HL.

Breast Cancer Res. 2012 Jul 5;14(4):R100. doi: 10.1186/bcr3219.

18.

A high-content assay to identify small-molecule modulators of a cancer stem cell population in luminal breast cancer.

Yoo BH, Axlund SD, Kabos P, Reid BG, Schaack J, Sartorius CA, LaBarbera DV.

J Biomol Screen. 2012 Oct;17(9):1211-20.

19.

Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch.

Haughian JM, Pinto MP, Harrell JC, Bliesner BS, Joensuu KM, Dye WW, Sartorius CA, Tan AC, Heikkilä P, Perou CM, Horwitz KB.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2742-7. doi: 10.1073/pnas.1106509108.

20.

Progesterone regulation of stem and progenitor cells in normal and malignant breast.

Axlund SD, Sartorius CA.

Mol Cell Endocrinol. 2012 Jun 24;357(1-2):71-9. doi: 10.1016/j.mce.2011.09.021. Review.

Items per page

Supplemental Content

Loading ...
Support Center